Koers bioMérieux Euronext Paris
Aandelen
FR0010096479
Medische apparatuur, benodigdheden & distributie
Omzet 2024 * | 3,9 mld. 4,17 mld. | Omzet 2025 * | 4,19 mld. 4,48 mld. | Marktkapitalisatie | 11,99 mld. 12,82 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 470 mln. 503 mln. | Nettowinst (verlies) 2025 * | 528 mln. 565 mln. | EV/omzet 2024 * | 2,99 x |
Nettoliquiditeiten 2024 * | 308 mln. 329 mln. | Nettoliquiditeiten 2025 * | 487 mln. 521 mln. | EV/omzet 2025 * | 2,74 x |
K/w-verhouding 2024 * |
26,1
x | K/w-verhouding 2025 * |
23,2
x | Werknemers | - |
Dividendrendement 2024 * |
0,86% | Dividendrendement 2025 * |
0,99% | Vrij verhandelbaar | 36,2% |
Recentste transcriptie over bioMérieux
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 01-11-16 |
Chairman | 50 | 16-04-04 | |
Director of Finance/CFO | 47 | 01-03-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 74 | 15-09-06 | |
Director/Board Member | 63 | 01-01-05 | |
Chairman | 50 | 16-04-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-10,29% | 7,61 mld. | |
+1,78% | 5,41 mld. | |
-1,16% | 4,51 mld. | |
+5,74% | 4,49 mld. | |
-50,70% | 3,29 mld. | |
+12,21% | 2,73 mld. | |
-16,13% | 2,02 mld. | |
-11,50% | 1,73 mld. | |
-5,02% | 1,64 mld. |